18 completed, 4 unknown, 2 terminated, 1 active not recruiting. 9 Phase 1, 9 Phase 2, 9 Phase 3, 4 Phase 4, 1 Not applicable.
Follow piperaquine: new trials by email Literature Review of piperaquine trials Research Report on piperaquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax) - Malaria | Phase 1 | Not yet recruiting | University of Oxford | 24 | 2026-11-01 | 2026-08-05 |
| Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia Dihydroartemisinin-piperaquine - Plasmodium Falciparum, Malaria | Phase 3 | Active not recruiting | PATH | 10350 | 2024-08-21 | 2025-05-06 |
| Southeast Asia Dose Optimization of Tafenoquine Tafenoquine, Chloroquine, Artemether 20 mg-Lumefantrine 120 mg - Plasmodium Vivax Malaria | Phase 4 | Recruiting | University of Oxford | 820 | 2024-07-22 | 2026-10-09 |
| In-vivo Transmission Model in Semi-immune Adults Piperaquine tablets , which will be administered orally as a single dose of 480mg (320mg+160mg)., Doxycycline (100mg tablets strength as Doxycycline Hyclate) will also be administered orally and will be given as 1 tablet (100mg) Once daily for 7 days. - Controlled Human Malaria Infection, Induced Blood Stage Malaria Infection | Phase 1 | Unknown | Ifakara Health Institute | 24 | 2024-01-09 | 2023-12-15 |
| Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso Sulphadoxine-Pyrimethamine/Amodiaquine, Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM) - Malaria | Phase 3 | Unknown | Malaria Consortium | 13000 | 2023-07-15 | 2023-11-22 |
| Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency Dihydroartemisinin, Piperaquine, Primaquine - Uncomplicated Plasmodium Falciparum | Phase 2 | Completed | Syamsudin Abdillah,Ph.D, Pharm D | 36 | 2022-11-01 | 2023-05-16 |
| Controlled Human Malaria Infection Transmission Model - Phase A PfSPZ Challenge, Sulfadoxine-Pyrimethamine, Piperaquine - Malaria,Falciparum | Phase 1 / Phase 2 | Suspended | University of Oxford | 44 | 2022-08-22 | 2024-05-23 |
| A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate Pyronaridine Tetraphosphate, Piperaquine tetraphosphate, Placebo - Healthy | Phase 1 | Completed | Medicines for Malaria Venture | 37 | 2022-02-14 | 2024-05-10 |
| Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) Dihydroartemisinin/Piperaquine, Tafenoquine 100mg [Arakoda] - Malaria, Falciparum | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 80 | 2020-10-29 | 2022-06-09 |
| Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Pyronaridine Tetraphosphate/Artesunate, Dihydroartemisinin/Piperaquine, Primaquine Diphosphate - Malaria,Falciparum | Phase 2 / Phase 3 | Completed | London School of Hygiene and Tropical Medicine | 100 | 2019-09-12 | 2020-01-30 |
| Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua Dihydroartemisinin, Piperaquine, Primaquine - Malaria,Falciparum, Malaria, Vivax | Phase 2 | Completed | Syamsudin Abdillah,Ph.D, Pharm D | 50 | 2019-01-11 | 2023-09-13 |
| Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 Piperaquine (low dose), Piperaquine (high dose), Sulfadoxine pyrimethamine - Malaria,Falciparum, Gametocytes | Not applicable | Completed | Radboud University Medical Center | 24 | 2018-05-07 | 2020-07-07 |
| Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP 480 mg Piperaquine phosphate, 640 mg Piperaquine phosphate, 200 mg OZ 439 - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 24 | 2018-04-23 | 2024-05-10 |
| Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1 Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose) - Malaria | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 29 | 2016-06-01 | 2018-03-23 |
| Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos KAE609, Piperaquine Phosphate - Plasmodium Falciparum Malaria | Phase 1 | Terminated | Novartis Pharmaceuticals | 8 | 2015-07-01 | 2019-07-23 |
| Experimental Falciparum Transmission to Anopheles Administration of the malaria inoculum, Piperaquine Phosphate 480 mg - Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 6 | 2015-04-01 | 2020-05-26 |
| Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria. Artefenomel 800mg: piperaquine 640mg, Artefenomel 800mg: piperaquine 960mg, Artefenomel 800mg: piperaquine 1440mg - Uncomplicated Plasmodium Falciparum Malaria | Phase 2 / Phase 3 | Completed | Medicines for Malaria Venture | 448 | 2014-07-01 | 2017-03-10 |
| Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria Eurartesim tablets - Malaria, Vivax | Phase 2 | Terminated | Alfasigma S.p.A. | 27 | 2014-06-18 | 2018-09-17 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO artemisinin/naphthoquine, dihydroartemisinin/piperaquine phosphate - Plasmodium Falciparum, Malaria, Falciparum | Phase 4 | Completed | Ifakara Health Institute | 60 | 2014-01-07 | 2018-03-14 |
| Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Dihydroartemisinin and piperaquine - Malaria | Unknown | INDEPTH Network | 10000 | 2013-09-01 | 2014-07-25 |
Showing 20 of 28. Sign in to see all of them.
Malaria (13) · Malaria, Falciparum (10) · Malaria, Vivax (6) · Infections (2) · Recurrence (1) · Schistosomiasis (1)
Medicines for Malaria Venture (5) · University of Oxford (5) · London School of Hygiene and Tropical Medicine (4) · Ifakara Health Institute (2) · Radboud University Medical Center (2) · Syamsudin Abdillah,Ph.D, Pharm D (2) · Alfasigma S.p.A. (1) · INDEPTH Network (1) · Malaria Consortium (1) · Novartis Pharmaceuticals (1) · Oxford University Clinical Research Unit, Vietnam (1) · PATH (1) · Papua New Guinea Institute of Medical Research (1) · Universiteit Antwerpen (1)
Indonesia (4) · Netherlands (4) · Australia (3) · Burkina Faso (3) · Tanzania (3) · Vietnam (3) · Mali (2) · Mozambique (2) · Switzerland (2) · Thailand (2) · Afghanistan (1) · Benin (1) · Cambodia (1) · Democratic Republic of the Congo (1) · Ethiopia (1)
Adam Bennett, PhD (1) · Alassane Dicko, PhD, MD (1) · Ally Olotu, MD,Dphil (1) · Ayodhia Pitaloka Pasaribu, MD (1) · Badara Cisse, PhD (1) · Christoph Hatz, Prof Dr Med (1) · Cindy Chu, MD, PhD (1) · Fiona Macintyre, PhD (1) · Fred N Binka, MD, PhD (1) · Ghulam R Awab, MD (1) · Gudissa Assefa Bayissa (1) · Henry Ntuku, MD, PhD (1) · Hiwot Teka (1) · James McCarthy, MD FRACP (1) · James McCarthy, Prof (1)
PMID 26654101, PMID 19784374, PMID 20409302, PMID 20574538, PMID 23926329, PMID 24063608, PMID 26917051, PMID 28988541, PMID 29389671, PMID 29482720, PMID 30967148, PMID 31146732, PMID 32239171, PMID 32312783, PMID 33199389, PMID 35028628, PMID 35465706, PMID 35544095, PMID 39609822, PMID 40689586